Kristen Ciombor is an Oncology physician affiliated with Vanderbilt University. OpenAlex indexes 193 publications with 14,852 citations (h-index 30); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 The Vanderbilt Clinic
Nashville, TN 372320001
Telephone
615-936-2000Provider last certified this registry record 25 Mar 2022.
Clinical trials
- Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
Sponsor: National Cancer Institute (NCI)
- Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Sponsor: Academic and Community Cancer Research United
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20253 payments
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- Exelixis Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
43.9%Serotonin-3 Receptor Antagonist30.6%Ondansetron Hcl53%Ondansetron Odt47%Part D<11 patientsAntidiarrheal microorganisms13.3%Creon100%Part D<11 patientsNervous system
28.6%Gabapentinoids15.3%Gabapentin100%Part D<11 patientsPhenothiazine13.3%Prochlorperazine Maleate100%Part D≥11 patientsBlood & clotting
15.3%Factor Xa inhibitor15.3%Xarelto100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2022–2026 per NIH RePORTER. The latest:
- Vanderbilt Network Lead Academic Participating Site for the NCTN
Vanderbilt University Medical Center
FY2026$367,000UG1CA233270 - Vanderbilt Network Lead Academic Participating Site for the NCTN
Vanderbilt University Medical Center
FY2025$438,545UG1CA233270 - Gastrointestinal Cancer Research Program
Vanderbilt University Medical Center
FY2025$339,812P30CA068485
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
James Crowe, MD
Vanderbilt University
Ingrid Mayer, MD
Vanderbilt University
Michael Debaun, MD
Vanderbilt University
Sam Chang, MD
Vanderbilt University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”